Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Inclusion Criteria: * Patients with newly diagnosed embryonal RMS, botryoid or spindle cell variants of embryonal RMS, ectomesenchymoma, or alveolar RMS are eligible for this study * Enrollment on COG-D9902 to confirm local histologic diagnosis with central pathology review is required for all patients * Patients may be enrolled on ARST0531 and start protocol treatment prior to receipt of central pathology review results * Patient must have Intermediate-risk RMS defined as: * Embryonal, botryoid, or spindle cell RMS, or ectomesenchymoma: stage 2 or 3 and group III OR * Alveolar RMS: stage 1-3 and group I-III * Staging ipsilateral retroperitoneal lymph node dissection (SIRLND) is required for all patients \>= 10 years of age with paratesticular tumors and for patients \< 10 years with clinically or radiographically involved lymph nodes (except when extensive lymph node involvement, defined as two or more lymph nodes \> 2 cm in dimension, is identified by imaging studies) * Regional lymph node sampling or sentinel lymph node procedure is required for histologic evaluation in patients with extremity tumors * Clinically or radiographically enlarged nodes should be sampled for histologic evaluation * Detection of metastasis by optional FDG PET (not required for study enrollment); FDG PET may detect abnormalities suggestive of metastasis not identified by bone scan, computed tomography (CT), or bone marrow aspiration/biopsy; the prognostic significance of FDG PET-detected abn…